Interim Analysis of a Phase 1 Study of PRTX007: Safety, PK and PD Response

Background

Toll-like receptor 7 (TLR7) is a key sensor of viral infection by ssRNA viruses.¹ Engagement leads to direct activation of plasmacytoid dendritic cell (pDCs) and B cells, and indirect, orchestrated engagement of many other immune cells.^{1,2} Furthermore, pDCs form an interferogenic synapse with virally infected cells,² targeting local interferon (IFN) production at the site of infection via paracrine transfers. A major limitation in targeting TLR7 is inflammation accompanying activation of 2 key intracellular pathways in pDCs, leading not only to biosynthesis of (a) all human Type I/III IFNs but also to (b) proinflammatory factors like IL-6, TNFα, and IL-1β via NF-κB. In COVID-19, cytokine release syndrome is a major driver of inflammation mediated in part by hyperactivation of the NF- κ B pathway. IL-6 and TNF α are key mediators of hyperinflammation.^{3,4} Therefore, any effective systemic TLR7 agonist must avoid aggravating this pathology.

PRTX007 is a prodrug of PRX034, a novel TLR7 agonist, for treatment of respiratory viral diseases, including those caused by SARS-CoV-2 (Figure 1A). PRX034 activates pDCs to preferentially synthesize poly subtype IFNs while minimizing NF-κB-mediated proinflammatory factors (Figure 1B). Preclinical studies with PRX034, for the first time demonstrated the ability to decouple these two normally linked processes in human PBMCs in vitro and in cynomolgus monkeys in vivo. Antiviral activity is preserved, as demonstrated in vitro (inhibition of cytopathicity and viral replication in RNA viruses by conditioned media from PRX034-treated PBMCs) and in vivo (efficacy and safety in a murine model of RSV infection) [unpublished data].



BTK=Bruton's tyrosine kinase; IL-6=interleukin 6; IRF7=interferon regulatory factor 7; IFN=interferon; IRAK-4=interleukin-1 receptor-associated kinase 4; NF-κB= nuclear factor-κB; pDC=plasmacytoid dendritienterleukin-1 receptor-associated kinase 4; NF-κB= nuclear factor-κB; pDC=plasmacytoid kinase 4; NF-κB= nuclear factor-κB; pDC=pla cell; TAK1=TGF-β-activated kinase 1; TRAF=tumor necrosis factor receptor (TNFR)-associated factor 6.

Figure 1. PRX034 induction of innate immunity without production of proinflammatory factors **A.** Structures of PRTX007 and PRX034 **B.** Signalling pathways activated by PRX034 binding to TLR7 in pDCs

Methods

Study Design

- This is a first-in-human, phase 1, single-center, prospective, randomized, double-blind, placebo-controlled study of 9 single-ascending dose (SAD) cohorts and 4 multiple-ascending dose (MAD) cohorts of PRTX007 administered orally to adult healthy volunteers (HVs; Figure 2). This phase 1 trial is ongoing in Sydney, Australia
- The primary objective is to assess the safety and tolerability of PRTX007 following SAD and MAD in normal HVs as measured by adverse events, vital signs, clinical laboratory data, electrocardiograms, and physical examinations
- Secondary objectives are to (1) assess the pharmacokinetic (PK) characteristics of PRX034, the active metabolite of prodrug PRTX007, (2) determine the effect of a high-fat meal on a single oral dose of PRTX007 and its metabolite in normal HVs, and (3) assess the pharmacodynamics (PD) of PRTX007 given as single and multiple doses in normal HVs, including reproducibility of key immune response markers
- Blood was collected from HVs and used for PD analysis of cytokines/chemokines, mRNA expression over 24 hours after dosing for all SAD cohorts
- For PK analysis, blood was collected over 48 hours
- This interim analysis focuses primarily on the SAD portion of the study of 8 dose levels from 50 mg to 600 mg (Figure 2) Safety, PK, and PD are presented for the first 8 SAD cohorts
- Safety data are presented from 300 mg to 400 mg MAD cohorts
- 64 of the 84 HVs in this interim analysis received drug

Part 1. Single ascending oral dose in healthy volunteers, placebo controlled														
Cohort 1	ohort 1 Cohort 2 Cohort 3 Cohort 4				Cohort 6	Cohort 7	Cohort 8	Cohort 13						
50 mg SAD	100 mg SAD	150 mg SAD	200 mg SAD	300 mg SAD	400 mg SAD	500 mg SAD	600 mg SAD	800 mg SAD Initiated Jan 2022						
Part 2. Multiple	e ascending ora	al dose in health	y volunteers, pl	acebo controlle	ed			Initiates Feb 2022						
				300 mg MAD	400 mg MAD	500 mg MAD		TBD mg MAD						
				Cohort 9	Cohort 10	Cohort 11		Cohort 12						
	SAD Cohort MAD Cohort Color													
6 treateFood et	ed and 2 placebo HVs ffect study at 100 mg		 8 treated Adminis	d and 2 placebo HVs tered QOD over 13 day	ys (7 doses)	Cohor	Cohorts with data shown in the interim analys							
		Planned doses												

Charlotte R. Lemech^{1,2}, Curtis L. Scribner³, Christopher Argent¹, Richard Daniels⁴, James R. Appleman⁴ ¹Scientia Clinical Research, LTD, Randwick, NSW, Australia; ²Prince of Wales Clinical School, UNSW Sydney, Australia; ³Curtis L. Scribner, Oakland, CA, USA; ⁴Primmune Therapeutics, Inc., Carlsbad, CA, USA

Results

Favorable Safety Profile and Tolerability

				Mild Moderate		Mild Moderate		Mild Moderate		Se	vere	Т	otal	A. Heat Orde	map demon red by increasing	strates constrates constrates constrates constrained by the second secon	oordinat osure to TLI	t ed re s R7 agonis	sponse	: upre	gulation	in res	ponse	to dru	g expo	sure						
	Total Group (N=84)	Related	Not Related	Related	Not Related	Related	Not Related	Related	Not Related		Blind ID	S-C4-E S-C4-A	S-C5-E	S-C5-B	S-C4-F S-C5-F	S-C6-F S-C4-C	S-C5-D	S-C6-D	S-C8-F S-C6-E	S-C5-C S-C7-A	S-C7-F	S-C6-A	S-C8-C	S-C7-E	S-C8-B	2-נס-נ S-C7-B	S-C7-C S-C8-E	S-C7-D S-C8-A				
Nervous System Disorders	Headache	8 (9.5%)	6 (7.1%)	2 (2.4%)	12 (14.3%)	-	_	10 (11.9%)	18 (21.4%)		AUC (hr*ng/mL)	2,607 2,913	3,092 4,171	4,721	4,878 5,020	5,311 5,398	5,547	6,736	6,761 7,067	7,070 7,111	7,118	7,915	8,220	9,919	10,261	11,208	12,030 14,260	15,750 17,178				
Cardiac Disorders											Dose (mg)	200 200 2	00 300 30	00 300	200 300	400 20	300 20	0 400 6	500 400	300 500	500 4	00 400	600 40	00 500	600 60	00 500	500 600 5	500 600				
	Tachycardia	1 (1.2%)	-	-	-	-	-	1 (1.2%)	-	Coordi	nated Response?				Y	Y		Y	Y	Y	Y	Y	Y	Y Y	YY	Y Y	ΥΥ	Y Y				
	Sinus Tachycardia	1 (1.2%)	-	-	-	-	-	1 (1.2%)	-	, s	IFIT1	0.0 0.6 1	5 0.7 0	0 0.6	1.4 0.9 1.0 0.3	0.7 2.9	0.4 0.8 0.2 0	8 2.0 0 4 0.6 0	0.0 1.9	2.3 1.1	2.7 1	.9 2.1	0.5 1.	.5 2.7	3.9 4.	5 2.5	3.1 5.0 5 1.1 1.7	5.0 4.5 2 8 2 3				
Gastrointestinal Disorders										ral ISG	ISG15	0.1 0.1 0 0.2 0.3 0	0.5 0.4 0	1 0.2	1.7 0.3	0.3 2.2	2 0.5 0.	9 1.5 0	0.2 0.0 0.4 1.7	2.2 1.0	2.2 0	.8 2.0	0.3 1.	.3 1.3	3.3 4.	.8 3.8	3.0 5.0	5.0 5.4				
	Loose Stool	1 (1.2%)	1 (1.2%)	-	-	-	-	-	2 (2.4%)	nge Antivi	MX1 OAS1	0.0 0.5 C	0.0 0.5 0 0.0 0.1 0	0 0.0 1 0.0	1.9 0.5 1.4 0.1	0.0 2.1	2 0.7 0. 0.3 0.	5 1.5 0 2 0.7 0	0.31.00.20.9	1.4 0.3 1.0 0.4	2.0 1 1.4 0	.1 1.9 .5 0.8	0.3 1. 0.0 0.	.6 1.5 .9 0.9	2.0 2. 1.4 2.	8 2.8 .5 2.2	3.0 3.9 4 2.3 3.0 4	4.0 3.7				
	Diarrhea	1 (1.2%)	-	-	_	-	-	-	1 (1.2%)	-Cha	OAS2	0.0 0.3 0	.6 0.3 0	0 0.1	2.0 0.2	0.3 2.5	0.3 0.	7 0.6 0	0.2 0.7	1.2 0.2	1.4 0	.6 1.2	0.3 0.	.9 0.7	0.8 2.	.2 2.7	2.0 3.1 5	3.6 3.4				
Hepatobiliary Disorders										Eold	CCL2 (MCP-1)	2.9 0.1 0	.0 2.6 1	1 0.5	2.6 0.3	1.3 3.4	1.4 1.	1 2.5 0	0.3 2.7	2.4 1.2	3.2 1	.4 5.2	2.8 2.	.4 3.9	6.1 6.	.1 5.1	8.5 6.4	7.8 7.1				
	Elevated ALT	4 (4.8%)	-	-	-	-	_	4 (4.8%)	_	Log ₂ nanisti iher)	CXCL10 (IP10)	0.3 1.0 3 0.5 0.0 0	.0 1.3 1 .0 0.4 0	7 1.9 0 0.3	2.0 0.8 1.6 0.7	2.3 2.6 0.1 0.8	0.9 1. 3 0.4 0.	1 3.5 0 6 0.5 0	0.03.90.60.8	0.1 0.3	1.6 0 1.2 1	.0 1.7 .1 0.6	0.3 0. 1.5 0.	.6 3.7 .4 0.1	3.1 6. 1.3 2.	33.5.32.7	5.2 6.5 1 1.5 1.7 4	0.1 6.6 4.1 3.7				
Musculoskeletal and Connect	ive Tissue Disorders									Mech (ot	IRF7	0.3 0.1 0	.1 0.5 0	0 0.0	1.2 0.3	0.1 1.3	0.3 0.	3 0.5 0	0.3 0.9	0.8 0.5		.6 0.9	0.4 0.	.8 0.4	1.3 2.	.5 2.4	2.0 2.9 5	3.6 3.4				
	Lower Back Pain	-	3 (3.6%)	1 (1.2%)	1 (1.2%)	-	_	1 (1.2%)	4 (4.8%)	 Valu	TLR7 es are ΔR _0-24h	0.0 0.9 1	.4 0.4 0	2 0.3 nt baselir	0.3 0.3	0.6 0.7	/ 0.1 0.	0 1.4 0	0.0 0.5	0.0 0.8	0.7 0	.8 0.3	0.4 0.	.8 1.2	0.5 1.	3 0.8	1.6 1.4 2	9 2.2				
Immune System Disorders		4 (4 224)								All H AUC	Vs receiving PRTX(=area under the pl	007 in the 200 asma drug cor	mg through	600 mg c ime curve	ohorts (n: e; ISG=inte	30) are sh erferon-stir	own. Color nulated ger	intensity is ne product	s as showi	n in scale.						Cc	lor Intensit	y Scale				
	Ihrombocytopenia	1 (1.2%)	-	-	-	-	-	1 (1.2%)	-	IFIT1	interferon-ind	uced protein	with tetrat	icopepti	de repea	ts 1		CCL2 (I	MCP-1)	C-C m	notif cher	nokine l	igand 2: I	MCP-1		M	in Max /	Color				

ALT=alanine aminotransferase; MAD=multiple-ascending dose

 Table 1. PRTX007 treatment-related adverse events (up through the 400 mg MAD cohort)

Treatment-related adverse events include mild to moderate headache

- Severity or frequency is not dose related, is of short duration, and is not associated with systemic symptoms
- One HV in the 400 mg and one HV in the 600 mg SAD cohorts had asymptomatic mild tachycardia attributed to PRTX007
- Two HVs in both the 300 mg MAD, and 400 mg MAD had mild increases in ALT that rapidly resolved after treatment
- There were no associated changes in aspartate transaminase, bilirubin, or alkaline phosphatase
- No stopping or dose modifications were required

Well-behaved PK of PRX034 Following Oral Administration of PRTX007



Figure 3. Human pharmacokinetics (SAD cohorts 1-8, 50-600 mg; MAD 9, 300 mg PRTX007)

• Rapid absorption and conversion of prodrug PRTX007 to agonist PRX034 following oral administration (Figure 3A)

• Targeted short duration of pulsatile exposure to PRX034 (Figure 3A)

- Duration of systemic exposure to PRX034 at pharmacologically active levels is consistent with activation of innate immune response without counter-regulation

- Dose-proportional increase in exposure to prodrug and active agonist (Figure 3B)
- Agonist/prodrug AUC ~1.7 for all HVs (Figure 3B)

Planned TBD dose

- Minimal change in exposure with high-fat meal (modest delay in absorption; brown box; Figure 3C)
- Exposure unchanged between first (D1, green) MAD and seventh (D13, light blue) MAD doses (gold box; Figure 3C)

Induction of IFN-Stimulated Gene Products (ISG) and Other TLR7-Associated Cvtokines Without NF-κB-Mediated Inflammatory Cytokines (IL-16, IL-6, TNFα)

Figure 4. Expression analysis (mRNA) from whole blood

	IFIT1 i	interferon-induced protein with tetratricopeptide repeats 1		CCL2 (MCP-1)	C-C motif chemokine ligand 2; MCP-1		in Ma	x Color
Antiviral ISGs	IFITM	interferon-induced transmembrane protein 1	istic	CXCL10 (IP-10)	C-X-C motif chemokine ligand 10; IP-10		L 2.0)
	ISG15	ISG15 ubiquitin-like modifier	thani other	IL1RN (IL-1RA)	interleukin 1 receptor antagonist; IL-1RA		$\frac{2}{2}$ 3.0	
	MX1	MX dynamin-like guanosine triphosphate (GTP)ase 1	Mec (c	IRF7	interferon regulatory factor 7		5 4.0 1 5.0)
	OAS1	2'-5'-oligoadenylate synthetase 1		TLR7	toll-like receptor 7		5 6.0 5 7 0	
	OAS2	2'-5'-oligoadenylate synthetase 2		-		-	7 10.	5

OAS2 2'-5'-oligoadenylate synthetase

• The induction of coordinated response was observed in the 200-600 mg dose groups; coordinated response rate increases with dose and is highly correlated with exposure to PRX034

• No HVs receiving placebo, or 50 mg, 100 mg, or 150 mg doses of PRTX007 in the SAD cohorts (n=34) exhibited coordinated induction; therefore, they were omitted from the graphic

B. Robust IFN-mediated response without induction of proinflammatory factors



• ISG15 mRNA induction increases with exposure to active agonist; accordingly, the magnitude of response is a function of dose. Shown are SAD

cohorts 1 through 8, 50 mg to 600 mg • ISG15 RNA levels are at, or exceeding, levels in the blood associated with antiviral therapeutic benefit based on reference to published ANA773

(a TLR7 agonist)^{5,6,}

• AUCs likely to be associated with therapeutic benefit for ISG15 are also indicated in the boxes in Figure 4B; benefit may be observed at lower exposure The dashed line is the geometric mean (ISG15) + 2*SD of placebo group

• No induction of proinflammatory factors (TNF α , IL-1 β , IL-6; right panel)

C. ISG15 time course: extended duration of PD response (SAD cohorts 1-8, 50-600 mg)

Log, scale Log, scale (individual response) 64 ☐ ● Robust Responders 128 **•** Robust Responders **Robust Responders** Responders Responders **Robust Responders** Responders Responders Individual response (means) Group geometric mean (± SEM) · · · 20 Time (hrs) ISG15=interferon-stimulated gene 15; PD=pharmacodynamic; SAD=single-ascending dose; SEM=standard error of the mean.

• There is an extended duration of PD response over 24 hours

HVs were classified by anonymized ID and color-coded by ISG15 fold-change.

- Nonresponders (clear) = ISG15 fold-change <2-fold (n=32)
- Responders (gold) = ISG15 fold-change from ≥ 2 to <5-fold (n=9)

Robust Responders (purple) = ISG15 fold-change ≥5-fold (n=7)

• The duration of PD response is in excess of duration of exposure to active levels of PRX034 (see also Figure 3A, PK analysis)

Presented at the 29th Conference on Retroviruses and Opportunistic Infections | February 12-16, 2022 | Virtual

IP10 Induction Demonstrates Coordinated Downstream Immune Cascade



00474

Figure 5. IP10 (CXCL10): breadth of immune induction

• Selected circulating markers induced by PRX034 exposure in 50-600 mg SAD

- IP10, IL-1RA, MCP1, TRAIL are expressed at high levels in plasma (data not shown for IL-1RA, MCP1, or TRAIL)
- IP10 protein levels and mRNA increase in response to drug exposure (Figure 5A and B)

gamma-induced protein 10; OAS1=2'-5'-oligoadenylate synthetase 1; pDC=plasmacytoid dendritic cell; TLR7=toll-like receptor 7.

- Panel A, n=48; Panel B, n=64 (this includes placebo-treated HVs)
- The inset for Panel B shows that in the lower exposure range, there are some responses that occur at lower magnitudes. These responders are above the dashed line (the dashed line [n=16] represents the geometric mean of IP10 mRNA + 2*SD of placebo group; therefore, responders above this line likely represent signal above noise)
- IP10 levels are at, or exceeding, levels in the plasma associated with antiviral therapeutic benefit based on reference to published ANA773 (a TLR7 agonist) data^{5,6}
- The AUC expected to be associated with therapeutic benefit for IP10 is indicated in the box in **Figure 5**; benefit may be observed at lower exposure
- There is no increase in circulating IFN α (<LOQ with standard assay); however, detectable increases in IFN β (<100 pg/mL) accompanied IP10 increase (**Figure 5A**, circles)
- IFNβ movement was not seen except in conjunction with those IP10 points highlighted in the 5 HVs with higher AUC exposures (Figure 5A, circles)

• Increased IP10 in plasma indicates activation of multiple cell types downstream from activated pDCs (see cell types in Figure 5C) • Inflammatory factor production is not observed even in the face of this profound immune stimulation (Figure 4B)

Conclusions

This phase 1 study demonstrates

- Efficient systemic delivery and well-behaved PK of TLR7 agonist PRX034 by oral administration of the prodrug PRTX007
- Dose-dependent and exposure-dependent coordinated induction of TLR7-mediated immune response
- Agonist exposure in excess of 4300 hr*ng/mL is required for pharmacologic activity
- Degree of immune induction well managed above threshold
- Expected pattern of coordinated TLR7-mediated immune induction observed without increases in IL-6, TNFα, IL-1β
- Magnitude of immune induction expected to translate to therapeutic benefit based on benchmarking to published clinical studies by Anadys Pharmaceuticals^{5,6,7}

• In sum, interim analysis of PRTX007 demonstrates a favorable safety profile with dose-dependent systemic exposure and demonstrated activation of innate immune response

References

- 1. Akira S, et al. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801.
- 2. Assil S, et al. Plasmacytoid dendritic cells and infected cells form an interferogenic synapse required for antiviral responses. Cell Host Microbe. 2019;25(5):730-745.e6.
- 3. Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. *Immunity*. 2020;52(5):731-733. 4. Pearce L, et al. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24(8):723-730.
- 5. Bergmann JF, et al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther. 2011;34(4):443-453. 6. Janssen HLA, et al. ANA773, an oral inducer of endogenous interferons that acts via TLR7, reduced serum viral load in patients chronically infected with HCV. *Hepatology*. 2009;50(4 suppl):1022A. 7. Fletcher S, et al. Preclinical and healthy volunteer clinical studies with ANA773, an oral prodrug of a toll-like receptor 7 (TLR7)-selective agonist, suggest therapeutic potential in patients chronically infected with hepatitis C virus (HCV). Presented at: 13th International Symposium on Viral Hepatitis and Liver Diseases; March 20-24, 2009; Washington, DC.

Disclosures

This study was funded by Primmune Therapeutics, Inc. James Appleman and Richard Daniels are employees and stockholders of Primmune Therapeutics, Inc. Charlotte Lemech, Christopher Argent, and Curtis Scribner are independent contractors for Primmune Therapeutics, Inc.

Acknowledgements

Medical writing services were provided by SCIENT Healthcare Communications and funded by Primmune Therapeutics, Inc. (Carlsbad, CA).